🔎 Trials Near Me

Domov › Akutna mieločna levkemija › Illinois › Chicago

Klinične študije za Akutna mieločna levkemija v Chicago, IL

26 študij za Akutna mieločna levkemija išče udeležence na lokacijah v Chicago in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.

Uradno besedilo študije (angleško)

Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
  • Mount Sinai Hospital Medical Center, Chicago
  • John H Stroger Jr Hospital of Cook County, Chicago
  • University of Illinois, Chicago
  • in še 1
Starost 40–75 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT05334069

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Vključevanje udeležencevFaza 1
  • University of Chicago Comprehensive Cancer Center, Chicago
Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06484062

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Vključevanje udeležencevFaza 2
  • Northwestern University, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Starost 18–59 · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Vključevanje udeležencevFaza 3
  • University of Chicago Medicine, Chicago
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Vključevanje udeležencevFaza 2
  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • in še 1
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT05564390

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Vključevanje udeležencevFaza 1
  • Lurie Children's Hospital-Chicago, Chicago
Do 21 let · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT07012044

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Vključevanje udeležencevFaza 2
  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Vključevanje udeležencevFaza 2
  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Vključevanje udeležencevFaza 2
  • Northwestern University, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Starost 18–59 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Vključevanje udeležencevFaza 3
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
6 Months – 21 Years · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Vključevanje udeležencevFaza 1/2
  • The University of Chicago Medical Center, Chicago
30 Days · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT04065399

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

Vključevanje udeležencevFaza 1/2
  • University of Chicago, Chicago
Starost 18 in več · Vsi spoli · Posodobljeno 11. sep. 2026 · NCT06969430

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

Vključevanje udeležencevFaza 3
  • Lurie Children's Hospital-Chicago, Chicago
Starost 1–25 · Vsi spoli · Posodobljeno 4. sep. 2026 · NCT07022678

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

Vključevanje udeležencevFaza 3
  • US-Chigago IL-UHCHICAGO, Chicago
Starost 18 in več · Vsi spoli · Posodobljeno 1. sep. 2026 · NCT07223814

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

Vključevanje udeležencevFaza 1
  • University of Chicago Comprehensive Cancer Center, Chicago
Starost 18–75 · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT05886049

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Vključevanje udeležencevFaza 1/2
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Do 22 let · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Vključevanje udeležencevFaza 3
  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
  • Comer Children's Hospital, Chicago
29 Days – 21 Years · Vsi spoli · Posodobljeno 24. avg. 2026 · NCT05183035

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Vključevanje udeležencevFaza 1
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Starost 18 in več · Vsi spoli · Posodobljeno 20. avg. 2026 · NCT06001788

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Vključevanje udeležencevOpazovalna študija
  • Northwestern Memorial Hospital, Chicago
  • Rush University Medical Center, Chicago
  • University of Illinois at Chicago, Chicago
  • in še 2
Vse starosti · Vsi spoli · Posodobljeno 6. jul. 2026 · NCT01351545

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Vključevanje udeležencevFaza 1
  • University of Chicago, Chicago
Starost 13 in več · Vsi spoli · Posodobljeno 5. maj 2026 · NCT04771572

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Vključevanje udeležencevFaza 1/2
  • Northwestern University, Chicago
Starost 18 in več · Vsi spoli · Posodobljeno 13. apr. 2026 · NCT05732103

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Vključevanje udeležencevFaza 1/2
  • Northwestern, Chicago
Starost 12 in več · Vsi spoli · Posodobljeno 24. mar. 2026 · NCT04988555

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Vključevanje udeležencevFaza 1
  • Northwestern Medicine, Chicago
Starost 12 in več · Vsi spoli · Posodobljeno 16. mar. 2026 · NCT06994676

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Vključevanje udeležencevFaza 1
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Starost 18 in več · Vsi spoli · Posodobljeno 13. mar. 2026 · NCT05735184

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

Vključevanje udeležencevFaza 1
  • Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago
Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2025 · NCT06501196

Študije za Akutna mieločna levkemija v drugih mestih

Druge študije v Chicago

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.